Article

Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
New England Journal of Medicine (Impact Factor: 54.42). 05/2012; 366(21):1978-86. DOI: 10.1056/NEJMoa1106126
Source: PubMed

ABSTRACT Women with cystic fibrosis are at increased risk for mucoid conversion of Pseudomonas aeruginosa, which contributes to a sexual dichotomy in disease severity.
We evaluated the effects of estradiol and its metabolite estriol on P. aeruginosa in vitro and in vivo and determined the effect of estradiol on disease exacerbations in women with cystic fibrosis.
Estradiol and estriol induced alginate production in P. aeruginosa strain 01 and in clinical isolates obtained from patients with and those without cystic fibrosis. After prolonged exposure to estradiol, P. aeruginosa adopted early mucoid morphology, whereas short-term exposure inhibited bacterial catalase activity and increased levels of hydrogen peroxide, which is potentially damaging to DNA. Consequently, a frameshift mutation was identified in mucA, a key regulator of alginate biosynthesis in P. aeruginosa. In vivo levels of estradiol correlated with infective exacerbations in women with cystic fibrosis, with the majority occurring during the follicular phase (P<0.05). A review of the Cystic Fibrosis Registry of Ireland revealed that the use of oral contraceptives was associated with a decreased need for antibiotics. Predominantly nonmucoid P. aeruginosa was isolated from sputum during exacerbations in the luteal phase (low estradiol). Increased proportions of mucoid bacteria were isolated during exacerbations occurring in the follicular phase (high estradiol), with a variable P. aeruginosa phenotype evident in vivo during the course of the menstrual cycle corresponding to fluctuating estradiol levels.
Estradiol and estriol induced mucoid conversion of P. aeruginosa in women with cystic fibrosis through a mutation of mucA in vitro and were associated with selectivity for mucoid isolation, increased exacerbations, and mucoid conversion in vivo. (Funded by the Molecular Medicine Ireland Clinician-Scientist Fellowship Programme.).

1 Bookmark
 · 
179 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cystic Fibrosis (CF) is a genetic disease with equal prevalence across sexes. However, women present worse lung function with faster function decline, earlier onset of bacterial colonization, more frequent pulmonary exacerbations (PE), greater bronchial hyper-responsiveness, and higher mortality rates after puberty than men. The etiology of this gender disparity remains elusive but female hormones have been implicated in several studies.
    BMC Pulmonary Medicine 10/2014; 14(1):165. DOI:10.1186/1471-2466-14-165 · 2.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adolescents and adults with cystic fibrosis now approach developmental milestones, including sexual and reproductive ones, at a similar time to their healthy peers. Yet, their sexual and reproductive health (SRH) is profoundly affected by their disease, and their SRH decisions can substantially affect their health. Navigation of SRH milestones in the context of cystic fibrosis needs education, guidance, and access to SRH services. In this Review, we discuss scientific knowledge of SRH in patients with cystic fibrosis across the life course and clinical practices for SRH within cystic fibrosis care. We identify crucial gaps in SRH education of patients and their access to resources and then present a model of care for provision of developmentally appropriate SRH education and care within cystic fibrosis services across the life course. This model emphasises the central importance of the cystic fibrosis team and service links to primary and specialist SRH care. Copyright © 2014 Elsevier Ltd. All rights reserved.
    12/2014; 3(1). DOI:10.1016/S2213-2600(14)70231-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die autosomal-rezessiv vererbte Mukoviszidose ist eine chronisch progrediente Systemerkrankung aller exokrinen Drüsen. Verursacht wird sie durch Mutationen im CFTR-Gen (,,cystic fibrosis transmembrane conductance regulator gene“), die in einer Präzipitation und Retention muköser Sekrete in den Ausführungsgängen der exokrinen Drüsen und einer Disposition der Atemwege zur Infektion resultieren.Die Diagnose wird anhand von pathologisch erhöhten Chloridkonzentrationen oder 2 obligat krankheitsauslösenden CFTR-Mutationen gestellt. Bei nicht informativer Genetik und/oder Chloridkonzentrationen im Intermediärbereich ist bei klinischem Verdacht eine weiterführende CFTR-Funktionsdiagnostik indiziert. Der Verlauf der gastrointestinalen und pulmonalen Manifestation muss durch regelmäßige standardisierte Kontrolluntersuchungen überwacht werden.Die Standardtherapie der gastrointestinalen Symptomatik beinhaltet die Substitution von magensäureresistenten Pankreasenzymen und fettlöslicher Vitamine sowie eine hochkalorische, fettreiche Ernährung. Wesentliche Säulen der gegenwärtigen Therapie der pulmonalen Symptomatik sind eine großzügige und frühzeitige antimikrobielle Chemotherapie, Inhalationen, antiinflammatorische Behandlung sowie Sport und Physiotherapie. Bei fortgeschrittenem pulmonalem Krankheitsprozess kommen zusätzlich Sauerstofflangzeittherapie, nichtinvasive Maskenbeatmung und letztlich eine Lungentransplantation in Frage.Die pulmonale Manifestation bestimmt für gegenwärtig nahezu 90 % der Patienten den Verlauf und die Prognose der CF. Eine möglichst frühe Diagnose und Betreuung an einem CF-Zentrum wirken sich günstig aus.
    Monatsschrift Kinderheilkunde 05/2013; 161(5). DOI:10.1007/s00112-012-2797-z · 0.28 Impact Factor

Full-text (2 Sources)

Download
41 Downloads
Available from
May 21, 2014